Mackenzie Financial Corp Has $35.33 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Mackenzie Financial Corp lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 86,827 shares of the pharmaceutical company’s stock after purchasing an additional 3,856 shares during the quarter. Mackenzie Financial Corp’s holdings in Vertex Pharmaceuticals were worth $35,329,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Arlington Trust Co LLC increased its stake in shares of Vertex Pharmaceuticals by 97.1% during the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 33 shares during the last quarter. Fortitude Family Office LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth $30,000. Baystate Wealth Management LLC increased its stake in shares of Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 25 shares during the last quarter. OFI Invest Asset Management acquired a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth $25,000. Finally, Cornerstone Planning Group LLC acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth $33,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 2,656 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $419.51, for a total value of $1,114,218.56. Following the completion of the transaction, the chairman now directly owns 27,644 shares of the company’s stock, valued at $11,596,934.44. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, COO Stuart A. Arbuckle sold 4,295 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares in the company, valued at approximately $31,819,732.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Jeffrey M. Leiden sold 2,656 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $419.51, for a total transaction of $1,114,218.56. Following the sale, the chairman now owns 27,644 shares of the company’s stock, valued at approximately $11,596,934.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,381 shares of company stock valued at $5,203,249. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.3 %

Shares of VRTX stock opened at $393.10 on Thursday. Vertex Pharmaceuticals Incorporated has a 12-month low of $316.43 and a 12-month high of $448.40. The company has a market capitalization of $101.60 billion, a P/E ratio of 28.30, a P/E/G ratio of 1.84 and a beta of 0.35. The firm has a 50-day moving average price of $414.76 and a 200 day moving average price of $396.76. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the previous year, the firm posted $3.33 earnings per share. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Maxim Group lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Royal Bank of Canada raised their price target on shares of Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 6th. Wolfe Research assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, February 15th. They issued an “outperform” rating and a $515.00 price target on the stock. JPMorgan Chase & Co. raised their price target on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Finally, Robert W. Baird lowered shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price target on the stock. in a research report on Wednesday, January 31st. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $424.62.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.